Best of Small Cell Lung Cancer (SCLC) 2025-Best of Small Cell Lung Cancer

Video Transcription

Video Summary

During the ISLC webinar "Best of SCLC 2025," Dr. Kristen Ko discussed neuroendocrine cell heterogeneity in small cell lung cancer (SCLC), focusing on various cell origin types and their significant implications in respiratory diseases. Through extensive molecular profiling and mouse models, she illustrated the diversity and plasticity of neuroendocrine cells during tumor progression and highlighted the development of a human neuroendocrine cell map to aid future research.<br /><br />Dr. Trudy Oliver shared insights on tumor cell plasticity in SCLC, emphasizing that basal cells can be a primary origin for various cancer cell subtypes, more accurately recapitulating the human disease's genetic diversity and plasticity compared to traditional models. Her work demonstrated how basal cells contribute to SCLC heterogeneity and could transform paradigms in understanding the tumor genesis and progression.<br /><br />Dr. Jacob Sands spoke about advancements in DLL3-directed therapies, namely, Tarlotumab, a bispecific T-cell engager that has shown efficacy in SCLC, marking a shift from traditional chemotherapy. He highlighted other emerging DLL3 therapies and CAR-T cell treatments, underscoring potential new standards for treatment and management of SCLC. Discussions also alluded to the future of SCLC treatment potentially moving away from chemotherapy towards innovative, targeted therapies. This webinar highlighted promising avenues and ongoing research, reshaping future SCLC treatment landscapes.

Keywords

neuroendocrine cell heterogeneity

small cell lung cancer

SCLC

tumor progression

DLL3-directed therapies

Tarlotumab

CAR-T cell treatments

tumor cell plasticity

basal cells

innovative therapies